Overview

Dose Escalation and Expansion Study of SYH2043 in Patients With Advanced Malignant Tumors

Status:
Not yet recruiting
Trial end date:
2026-03-01
Target enrollment:
Participant gender:
Summary
The aim of this study is designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of SYH2043 in patients with advanced malignant tumors.
Phase:
Phase 1
Details
Lead Sponsor:
CSPC Ouyi Pharmaceutical Co., Ltd.